Lupin mulls internal restructuring options, looks to separate its API business: Report
Lupin is reportedly considering a demerger of its active pharmaceutical ingredients (API) business, following in the footsteps of Glenmark Pharma. The specifics of the demerger, such as a potential listing or stake sale, are yet to be determined.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
